FEDERAL COURT OF AUSTRALIA
F.Hoffman-La Roche AG v New England Biolabs Inc [2000] FCA 283
PATENTS – patent application – claims in relation to a purified thermostable DNA polymerase – appeals from decision of a delegate of the Commissioner of Patents pursuant to s 60(5) of the Patents Act 1952 (Cth) – nature of an appeal from an opposition hearing before a delegate – whether appeal a full hearing of factual issues on the merits – nature of onus – whether it must be “practically certain” that patent would be invalid – whether Court should permit grant unless “quite clear” that patent would not stand – whether opponent’s case must be “clearly” made out – whether legislative scheme limits scope of appeal – whether nature of appeal limits evidence that may be adduced – whether evidence of a particular expert relevant
Patents Act 1952 (Cth) ss 59(1), 60(1), 60(5), 146(1), 148(2), 150; Pt V
Patents Act 1990 (Cth) ss 3, 19, 19(1), 138, 138(3), 154(1), 158(2), 160; Sch 1
Federal Court of Australia Act 1976 (Cth) ss 24, 24(1A)Genetics Institute Inc v Kirin-Amgen Inc (1999) 163 ALR 761 referred to
McGlashan v Rabett (1909) 9 CLR 223 referred to
Stamp v Powell Pty Ltd (1918) 24 CLR 339 cited
Henry Berry & Co Pty Ltd v Potter (1924) 35 CLR 132 referred to
Commissioner of Patents v Microcell Ltd (1959) 102 CLR 232 considered
Kaiser Aluminium & Chemical Corp v Reynolds Metal Co (1969) 120 CLR 136 cited
Farmwerke Hoechst Aktiengesellschaft Vormals Meister Lucius v Commissioner of Patents (1971) 45 ALJR 235 referred to
Montecatini Edison S.p.A v Eastman Kodak Co (1971) 45 ALJR 593 considered
General Electric Co.’s Applications [1964] RPC 413 referred to
Dennison Manufacturing Co v Monarch Marking Systems Inc (1981) 51 AOJPTMD 1716 referred to
Dennison Manufacturing Co v Monarch Marking Systems Inc (1983) 66 ALR 265 referred to
R D Werner Co Inc v Bailey Aluminium Products Pty Ltd (1987) 8 IPR 339 referred to
R D Werner Co Inc v Bailey Aluminium Products Pty Ltd (1989) 25 FCR 565 referred toON APPEAL FROM THE COMMISSIONER OF PATENTS
F.HOFFMAN-LA ROCHE AG v NEW ENGLAND BIOLABS INC
NG 947 OF 1997NEW ENGLAND BIOLABS INC v F.HOFFMAN-LA ROCHE AG
NG 1035 OF 1997EMMETT J
28 APRIL 2000
SYDNEY
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
NG 947 OF 1997
ON APPEAL FROM THE COMMISSIONER OF PATENTS
BETWEEN:
F.HOFFMAN-LA ROCHE AG
APPLICANTAND:
NEW ENGLAND BIOLABS INC
RESPONDENTNG 1035 OF 1997
ON APPEAL FROM THE COMMISSIONER OF PATENTS
BETWEEN:
NEW ENGLAND BIOLABS INC
APPLICANTAND:
F.HOFFMAN-LA ROCHE AG
RESPONDENTJUDGE:
EMMETT J
DATE:
28 APRIL 2000
PLACE:
SYDNEY
EX TEMPORE REASONS FOR DECISION
I have before me two appeals arising out of opposition proceedings under the provisions of the Patents Act 1952 (Cth) (“the 1952 Act”) as continued in force under the Patents Act 1990 (Cth) (“the 1990 Act”). F. Hoffman-La Roche AG (“the Applicant”)…
Keep reading for free
Create a free CaseChat account to read F.Hoffman-La Roche AG v New England Biolabs Inc and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2000] FCA 283
- Decision Date
CaseChat Overview and Summary
The court found that the appeal was not limited to the scope prescribed by the legislative scheme and allowed for a full hearing of the factual issues on the merits. The court held that the onus was on New England Biolabs to clearly establish that the patent would be invalid. The court further determined that evidence presented by New England Biolabs, even if acquired after the priority date, was relevant to the case being pursued. The court held that the nature of the appeal did not limit the evidence that could be adduced, and the onus on New England Biolabs was not to establish that it was "practically certain" that the patent would be invalid, but rather to clearly make out their case.
In conclusion, the court allowed New England Biolabs to present evidence that was relevant to their case, even if acquired after the priority date. The court found that the appeal was not limited by the legislative scheme and allowed for a full hearing of the factual issues on the merits. The onus was on New England Biolabs to clearly establish that the patent would be invalid. The final orders of the court were that New England Biolabs could present the evidence they wished to adduce, and the appeal would proceed to a full hearing on the merits.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Established by: EMMETT J
Dr Annabelle Bennett, senior counsel for the Applicant, contends that it would be erroneous to permit such evidence to be adduced, since it relates to knowledge acquired after the priority date. However, the fact which New England Biolabs wishes to establish is not that such knowledge was relevant to the question of novelty as at the priority date but that such knowledge enables one to determine today whether, as a matter of fact, there was in Kaledin's solution the enzyme in question. As I have said, whether that is sufficient to constitute novelty is a different question all together. Gel Filtration The second factual matter to which Dr Mosbaugh’s affidavit relates concerns the process of gel filtration. Gel filtration is a third method for determining the molecular weight of a protein. Gel filtration is a process which can be used as part of a purification procedure as well as a means to estimate the molecular weight of an unknown sample, as it separates proteins on the basis of size. This is another aspect, so far as New England Biolabs’ case is concerned, of the attempt to distinguish or explain the discrepancy in the Kaledin Paper. New England Biolabs proposes to adduce evidence that will establish that the inventors described in the Applicant’s Specification observed that the enzyme of Claim 1 tends to stick to a gel filtration resin. Accordingly, if the proposition advanced by Dr Mosbaugh is correct, during gel filtration the enzyme in question will exhibit a lower apparent molecular weight value than its actual molecular weight or a lower molecular weight than would be derived using other techniques. That again is relied on as a basis for explaining why those responsible for the Kaledin Paper may have determined a molecular weight below that described in Claim 1, but nevertheless isolated the same enzyme. For the reasons I have briefly given, I consider that that evidence is relevant to the case sought to be mounted on behalf of New England Biolabs. Again, as I have said, whether that is sufficient to establish lack of novelty is a different question altogether. Phosphocellulose Chromotography The third matter relied on concerns a different question, but it is related to the relationship that the Kaledin Paper bears to Claim 1 and the ancillary claims. One possibility that has been foreshadowed to explain why Kaledin Paper shows a molecular weight of 62,000 by SDS-PAGE is that the authors in fact isolated a fragment of the enzyme described in Claim 1, rather than a full length enzyme and that they did not at any time isolate the full length enzyme itself. The third area of disputed factual material is designed to establish that the Stoffel Fragment behaved in a different way from the enzyme identified in the Chien Paper, which New England Biolabs says is the same enzyme identified in the Kaledin Paper. Once again, I consider that this material is relevant to the case which New England Biolabs has foreshadowed that it wishes to pursue. Again, I comment that it may not necessarily be decisive one way or the other. However, in order to enable the question to be raised, I consider that it is relevant for New England Biolabs to establish that a fragment of the enzyme described in Claim 1 behaves in a way that is likely to be different from the enzyme described in the Kaledin Paper.